Supplementary Materials

Supplementary Material for:

A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft

Thusitha Gajanayake, Radu Olariu, Franck M. Leclère, Ashish Dhayani, Zijiang Yang, Anjan K. Bongoni, Yara Banz, Mihai A. Constantinescu, Jeffrey M. Karp,* Praveen Kumar Vemula,* Robert Rieben,* Esther Vögelin

*Corresponding author. E-mail: robert.rieben@dkf.unibe.ch (R.R.); praveenv@instem.res.in (P.K.V.); jmkarp@partners.org (J.M.K.)

Published 13 August 2014, Sci. Transl. Med. 6, 249ra110 (2014)
DOI: 10.1126/scitranslmed.3008778

This PDF file includes:

  • Fig. S1. Determination of plasma markers for kidney and liver damage.
  • Table S1. Transformation of TGMS-encapsulated tacrolimus from gel to liquid phase.
  • Table S2. Statistical analysis of enzyme-responsive tacrolimus release (raw data of Fig. 1C).
  • Table S3. Enzyme-responsive tacrolimus release (raw data of Fig. 1D).
  • Table S4. Tacrolimus release in response to conditioned medium from activated macrophages (raw data of Fig. 1F).
  • Table S5. Vascular composite allograft survival (raw data of Fig. 2A).
  • Table S6. Fluorescence intensities measured for IgG and IgM staining (raw data of Fig. 3, A to D).
  • Table S7. Plasma levels of anti-donor IgG (raw data of Fig. 3E).
  • Table S8. Plasma levels of anti-donor IgM (raw data of Fig. 3F).
  • Table S9. Fluorescence intensities measured for C3c deposition in skin and muscle tissues (raw data of Fig. 4, A and B).
  • Table S10. Quantitative analysis of cytokines in plasma in pg/ml (raw data of Fig. 4C).
  • Table S11. Plasma (ng/ml) and tissue (ng/g) levels of tacrolimus (raw data of Fig. 5, A and B).
  • Table S12. Palpability and volume of hydrogel depots (raw data of Fig. 6, A and D).

[Download PDF]